Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $628.43 million. The enterprise value is $521.84 million.
Important Dates
The last earnings date was Tuesday, March 18, 2025, after market close.
Earnings Date | Mar 18, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TRVI has 96.68 million shares outstanding. The number of shares has increased by 2.97% in one year.
Current Share Class | 96.68M |
Shares Outstanding | 96.68M |
Shares Change (YoY) | +2.97% |
Shares Change (QoQ) | +4.67% |
Owned by Insiders (%) | 1.01% |
Owned by Institutions (%) | 59.49% |
Float | 73.67M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 6.11 |
P/TBV Ratio | 6.31 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.41, with a Debt / Equity ratio of 0.01.
Current Ratio | 10.41 |
Quick Ratio | 10.29 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -12,881.00 |
Financial Efficiency
Return on equity (ROE) is -52.59% and return on invested capital (ROIC) is -34.90%.
Return on Equity (ROE) | -52.59% |
Return on Assets (ROA) | -32.15% |
Return on Invested Capital (ROIC) | -34.90% |
Return on Capital Employed (ROCE) | -51.32% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.84M |
Employee Count | 26 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -30,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +87.32% in the last 52 weeks. The beta is 0.91, so TRVI's price volatility has been similar to the market average.
Beta (5Y) | 0.91 |
52-Week Price Change | +87.32% |
50-Day Moving Average | 4.86 |
200-Day Moving Average | 3.55 |
Relative Strength Index (RSI) | 66.37 |
Average Volume (20 Days) | 4,389,232 |
Short Selling Information
The latest short interest is 4.68 million, so 4.84% of the outstanding shares have been sold short.
Short Interest | 4.68M |
Short Previous Month | 3.79M |
Short % of Shares Out | 4.84% |
Short % of Float | 6.35% |
Short Ratio (days to cover) | 1.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -51.52M |
Pretax Income | -38.78M |
Net Income | -47.91M |
EBITDA | -51.38M |
EBIT | -51.52M |
Earnings Per Share (EPS) | -$0.47 |
Full Income Statement Balance Sheet
The company has $107.62 million in cash and $1.03 million in debt, giving a net cash position of $106.59 million or $1.10 per share.
Cash & Cash Equivalents | 107.62M |
Total Debt | 1.03M |
Net Cash | 106.59M |
Net Cash Per Share | $1.10 |
Equity (Book Value) | 99.64M |
Book Value Per Share | 1.06 |
Working Capital | 98.92M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$38.26 million and capital expenditures -$35,000, giving a free cash flow of -$38.29 million.
Operating Cash Flow | -38.26M |
Capital Expenditures | -35,000 |
Free Cash Flow | -38.29M |
FCF Per Share | -$0.40 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |